CAMP4 Secures EMA Orphan Designation, Files CMP-002 Trial in Australia, $99M Cash Runway
CAMP4 submitted its first regulatory filing for CMP-002 in Australia, received EMA Orphan Designation, and plans a global Phase 1/2 trial in SYNGAP1 patients in 2H 2026. The company ended Q1 with $99.2 million in cash, funding operations into 2028, while posting $18.3 million net loss versus $12.4 million year-ago.
1. Q1 Financial Results
For the quarter ended March 31, 2026, CAMP4 reported research and development expenses of $10.2 million, general and administrative expenses of $4.2 million, and a net loss of $18.3 million compared to $12.4 million in Q1 2025.
2. Regulatory Milestones
The company submitted a regulatory filing for CMP-002 in Australia, plans additional global filings throughout 2026, and received Orphan Designation from the European Medicines Agency for CMP-002.
3. Collaboration and Scientific Advances
CAMP4 entered a collaboration with CURE SYNGAP1 to support the ProMMiS natural history study, submitted a preprint on its regRNA Capture-seq methodology, and appointed Michael MacLean to its board of directors.
4. Cash Position and Runway
Cash and cash equivalents totaled $99.2 million as of March 31, 2026, which is expected to fund planned clinical and preclinical activities into 2028.